<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="635">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05152888</url>
  </required_header>
  <id_info>
    <org_study_id>2021P003360</org_study_id>
    <nct_id>NCT05152888</nct_id>
  </id_info>
  <brief_title>The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk</brief_title>
  <acronym>EMPOWER</acronym>
  <official_title>The Impact of Pcsk-9 Inhibition on PET Coronary Flow Reserve in Patients at High Cardiovascular Risk (EMPOWER Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study protocol is a single-arm, open label pilot study designed to evaluate the impact of&#xD;
      PCSK-9 inhibition on coronary blood flow in patients with stable coronary artery disease.&#xD;
      Patients with stable coronary artery disease will be recruited from the BWH Cardiovascular&#xD;
      Medicine clinic and/or from the BWH Nuclear Cardiology Laboratory. A target sample size of 35&#xD;
      participants will undergo imaging with N-13 ammonia positron emission tomography (PET) and&#xD;
      coronary computed tomography angiography (CCTA) before and after 12 months of PCSK-9&#xD;
      inhibition with Evolocumab to assess changes in myocardial blood flow, plaque volume, and&#xD;
      vascular endothelial function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose an open-label investigator-initiated trial to directly test whether PCSK-9&#xD;
      inhibition with Evolocumab in patients with stable CAD improves PET CFR and stress MBF. To&#xD;
      further elucidate the possible mechanisms by which myocardial blood flow improves with PCSK-9&#xD;
      inhibition, we will assess changes in endothelial function and inflammatory biomarkers. The&#xD;
      findings of this translational study will provide a physiological read-out of the&#xD;
      comprehensive effects of Evolocumab on tissue perfusion, endothelial function, and&#xD;
      microvascular function in a high-risk population. As such, these data would serve to provide&#xD;
      a mechanistic explanation for why Evolocumab may reduce cardiovascular events beyond a&#xD;
      reduction in plaque burden and composition.&#xD;
&#xD;
      The central hypothesis of this study is that PCSK-9 inhibition will quantitatively improve&#xD;
      myocardial blood flow as measured by positron emission tomography (PET) in patients with&#xD;
      stable coronary artery disease. We postulate that the improvement in myocardial blood flow&#xD;
      will correlate with an improvement in endothelial cell function and a reduction in&#xD;
      inflammatory biomarkers, and not simply an improvement in coronary epicardial plaque burden.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study protocol is a single-arm, open label pilot study.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary Flow Reserve</measure>
    <time_frame>Change (from baseline) in global CFR, as measured by PET imaging at 52 weeks after initiation of Evolocumab therapy.</time_frame>
    <description>Change in global coronary flow reserve (CFR) after 12 months of therapy with Evolocumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stress Myocardial Blood Flow (MBF)</measure>
    <time_frame>Change (from baseline) in stress MBF, as measured by PET imaging at 52 weeks after initiation of Evolocumab therapy.</time_frame>
    <description>Change in stress Myocardial Blood Flow (MBF) after 12 months of therapy with Evolocumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Perfusion Deficit (TPD)</measure>
    <time_frame>Change (from baseline) in TPD, as measured by PET imaging at 52 weeks after initiation of Evolocumab therapy.</time_frame>
    <description>Change in Total Perfusion Deficit (TPD) after 12 months of therapy with Evolocumab</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Stable Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Evolocumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Informed consent will be obtained from study participants willing to participate in EMPOWER. Study participants will then undergo the baseline rest/stress cardiac PET scan along with CCTA. The final PET scan and CCTA will occur at 12 months after the intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>Evolocumab is a human monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9). Evolocumab was FDA approved in 2015 for the treatment of hyperlipidemia and subsequently approved in 2017 for the prevention of stroke and heart attack. 140mg single use SureClick autoinjector that is administered subcutaneously once every 2 weeks.</description>
    <arm_group_label>Evolocumab</arm_group_label>
    <other_name>Repatha</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: ≥ 50 (men) or ≥ 55 (women)&#xD;
&#xD;
          -  Low-density lipoprotein cholesterol (LDL-C) &gt; 90 mg/dL&#xD;
&#xD;
          -  Stable coronary artery disease (without plan to undergo revascularization before&#xD;
             randomization) defined as one or more of the following:&#xD;
&#xD;
               1. Abnormal nuclear perfusion imaging&#xD;
&#xD;
                    1. At least moderate ischemia involving &gt;10% of the LV myocardium or&#xD;
&#xD;
                    2. Global coronary flow reserve (CFR) &lt;1.8 or&#xD;
&#xD;
                    3. Stress myocardial blood flow (MBF) &lt;1.8&#xD;
&#xD;
               2. Abnormal coronary angiography (invasive coronary angiography or coronary computed&#xD;
                  tomography)&#xD;
&#xD;
                    1. &gt; 50% stenosis in &gt; 2 coronary vessels or&#xD;
&#xD;
                    2. Diffuse atherosclerosis in a 3-vessel distribution&#xD;
&#xD;
               3. Elevated coronary calcium score&#xD;
&#xD;
                    1. CAC &gt;100 + &gt;1 ASCVD risk factor&#xD;
&#xD;
                    2. CAC &gt;300&#xD;
&#xD;
          -  If the patient is on a statin they must be on a stable dose for at least 3 months&#xD;
             prior to enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of myocardial infarction or stroke&#xD;
&#xD;
          -  CABG &lt; 3 months prior to screening&#xD;
&#xD;
          -  Homozygous familial hypercholesterolemia&#xD;
&#xD;
          -  History of cardiac transplantation&#xD;
&#xD;
          -  LV ejection fraction &lt; 40% or New York Heart Failure Association (NYHA) class III-IV&#xD;
             for angina and/or dyspnea.&#xD;
&#xD;
          -  History of infiltrative or hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Severe valvular disease&#xD;
&#xD;
          -  Uncontrolled or recurrent ventricular tachycardia&#xD;
&#xD;
          -  Fasting triglycerides &gt; 500 mg/dL&#xD;
&#xD;
          -  GFR ˂ 30 mL/min/1.73 m²&#xD;
&#xD;
          -  Current use of a PCSK-9 inhibitor&#xD;
&#xD;
          -  Currently pregnant or breastfeeding&#xD;
&#xD;
          -  Contraindication to receive vasodilator agent&#xD;
&#xD;
          -  Latex allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marcelo Di Carli, MD</last_name>
    <phone>617-732-6290</phone>
    <email>mdicarli@bwh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Courtney Bibbo, M.Sc.</last_name>
    <phone>617-525-8322</phone>
    <email>cfbibbo@partners.org</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Marcelo F. Di Carli, MD, FACC</investigator_full_name>
    <investigator_title>Chief, Nuclear Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

